Formulary
Glecaprevir with pibrentasvir: Indications, Dosing, Side Effects and Interactions
Glecaprevir with pibrentasvir clinical drug profile including indications, dosing, side effects, cautions and interactions.
MedNext Academy | 3 min read
Glecaprevir with pibrentasvir: Indications, Dosing, Side Effects and Interactions
Glecaprevir with pibrentasvir clinical drug profile including indications, dosing, side effects, cautions and interactions.
Indications and dose
**Chronic hepatitis C (specialist use only)**
- **Adult** (By Mouth): 300/120 mg once daily, for duration of treatment, consult product literature.
**Chronic hepatitis C (specialist use only) for glecaprevir with pibrentasvir**
- **Child 12-17 years** (By mouth): 300/120 mg once daily, for duration of treatment, consult product literature.
Cautions
For glecaprevir with pibrentasvir Hepatitis B infection; post-liver transplant patients; re-treatment of patients with prior exposure to NS3/4A- or NS5A-inhibitors-efficacy not established
Side effects
For glecaprevir with pibrentasvir Common or very common Asthenia; diarrhoea; headache; nausea Uncommon Angioedema Frequency not known Hepatitis B reactivation; pruritus; transient ischaemic attack
Interactions
**Severe interactions:**
- Clinically significant increases in exposure were not observed for sensitive substrates of CYP3A (midazolam, felodipine) or UGT1A1 (raltegravir) when administered with Glecaprevir/Pibrentasvir.
- John's wort ( Hypericum perforatum ), phenobarbital, phenytoin, and primidone) could significantly decrease glecaprevir or pibrentasvir plasma concentrations and may lead to reduced therapeutic...
- Additional drug-drug interaction studies were performed with the following medical products and showed no clinically significant interactions with Glecaprevir/Pibrentasvir: abacavir, amlodipine,...
**Other interactions (20):**
- Co-administration with Glecaprevir/Pibrentasvir may increase plasma concentrations of medicinal products that are substrates of P-gp (e.g.
- Potential for other medicinal products to affect Glecaprevir/Pibrentasvir Use with strong P-gp/CYP3A inducers Medicinal products that are strong P-gp and CYP3A inducers (e.g., rifampicin,...
- Co-administration of Glecaprevir/Pibrentasvir with medicinal products that are moderate inducers P-gp/CYP3A may decrease glecaprevir and pibrentasvir plasma concentrations (e.g.
- Co-administration of Glecaprevir/Pibrentasvir with medicinal products that inhibit P-gp and BCRP (e.g.
- Medicinal products that inhibit OATP1B1/3 (e.g.
- Table 3: Interactions between Glecaprevir/Pibrentasvir and other medicinal products Medicinal product by therapeutic areas/possible mechanism of interaction Effect on medicinal product levels C max...
Pregnancy
For glecaprevir with pibrentasvir Manufacturer advises avoid-limited information available.
Breast feeding
For glecaprevir with pibrentasvir Manufacturer advises avoid-present in milk in animal studies.
Hepatic impairment
For glecaprevir with pibrentasvir Manufacturer advises avoid in moderate to severe impairment (risk of increased exposure).
Medicinal forms
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Glecaprevir with pibrentasvir in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary

